In collaboration with Bristol Myers Squibb, we commenced an investigator-initiated Phase 1/2 trial of Plinabulin at Rutgers University in combination with Opdivo (nivolumab), a PD-1 antibody, and Yervoy (ipilimumab), a CTLA-4 antibody, as a treatment for small cell lung cancer (SCLC). This study investigates whether the addition of Plinabulin results in a reduction of immune-related side effects of PD-1 and CTLA-4 antibodies and provides efficacy synergy.
Following on the demonstration that Plinabulin potently matures dendritic cells to boost the targeting of cancer cells by the immune system, BeyondSpring is focusing future clinical efforts establishing the anti-cancer effects of Plinabulin on the "Triple Combo" strategy. The first major step in this direction is underway, through an active nonclinical and clinical collaboration with MD Anderson. Initial Phase 1b/2 trials will treat patients that have progressed on PD-1/PD-L1 therapy with continued PD-1/PD-L1 plus radiation or chemotherapy to increase cancer cell neo-antigen generation and antigen availability, plus Plinabulin to boost neo-antigen presentation by dendritic cells to T-cells. Trials will assess safety, anti-cancer efficacy, and potential immunological prediction and response biomarkers.
For details of these two trials, please visit below websites.